HALLE (SAALE) / Munich, Germany, 04 August 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced that the U.S. Food and Drug Administration (FDA) […]
HALLE (SAALE) / Munich, Germany, 15 July 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced that the first patient has been enrolled in […]
Vivoryon and the Alzheimer’s Disease Cooperative Study (ADCS) have developed a new trial design for Phase 2a Alzheimer’s trial in the US; as a stage gate […]
HALLE (SAALE) / MUNICH, Germany, 14 May 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today its first quarter business update for the period […]
HALLE (SAALE) / Munich, Germany, 12 May 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced the postponement of the Annual General Meeting which […]
HALLE (SAALE) / Munich, Germany, 7 May 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), which develops first-in-class drugs targeting post-translational modifying enzymes, will publish […]
MorphoSys will not execute the option deal to license Vivoryon’s small molecule QPCTL inhibitors for oncology Vivoryon will continue to evaluate QPCTL inhibitors in oncology […]
HALLE (SAALE) / MUNICH and LEIPZIG, Germany, 16 April 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today that the Company has entered […]
This is a correction of the announcement from 07:00 am CET March 26, 2020. Reason for the correction: > As of December 31, 2019, the Loss […]